Primary Chemoablation of Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Using UGN-102, A Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial.

K. Kent Chevli,Neal D. Shore,Andrew Trainer,Angela B. Smith,Daniel Saltzstein,Yaron Ehrlich,Jay D. Raman,Boris Friedman,Richard D’Anna,David L. Morris,Brian Hu,Mark D. Tyson,Alexander Sankin,Max Kates,Jennifer Linehan,Douglas S. Scherr,Steven Kester,Michael Verni,Karim Chamie,Lawrence Karsh,Arnold Cinman,Andrew Meads,Soumi Lahiri,Madlen Malinowski,Nimrod Gabai,Sunil Raju,Mark P. Schoenberg,Elyse Seltzer,William C. Huang

Primary Chemoablation of Low-Grade Intermediate-Risk Non-Muscle-Invasive Bladder Cancer Using UGN-102, A Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial.

2021

Purpose:Low-grade intermediate-risk non-muscle-invasive bladder cancer (LG IR NMIBC) is a recurrent disease, thus requiring repeated transurethral resection of bladder tumors (TURBT) under general ...

Keywords:

Resection
recurrent disease
Clinical trial
Bladder cancer
Medicine
non muscle invasive
intermediate risk
Urology
open label

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations